Asymmetric Research and OtterSec Announce Shared Leadership to Meet Rising Blockchain Security Demands

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Asymmetric Research, a specialized security firm focused on long-term partnerships with L1s, L2s, and DeFi teams, and OtterSec, a technical audit company known for uncovering complex vulnerabilities, have formalized a shared leadership model that brings together two of the most technical teams in blockchain and web3 security. […]

Asymmetric Research and OtterSec Announce Shared Leadership to Meet Rising Blockchain Security Demands

Asymmetric Research and OtterSec Announce Shared Leadership to Meet Rising Blockchain Security Demands GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Asymmetric Research, a specialized security firm focused on long-term partnerships with L1s, L2s, and DeFi teams, and OtterSec, a technical audit company known for uncovering complex vulnerabilities, have formalized a

Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Eczema, a chronic inflammatory skin condition, significantly impacts patients' quality of life through persistent itching and irritation. The market is being driven by growing awareness, increasing diagnosis rates, and the expanding availability of advanced therapies. The introduction of

Bitcoin Munari Transitions to $0.50 Presale Round While ADA Holds $0.40 Support Amid Bullish Forecasts

Bitcoin Munari Transitions to $0.50 Presale Round While ADA Holds $0.40 Support Amid Bullish Forecasts GlobeNewswire December 08, 2025 Bitcoin Munari has entered the fourth round of its public presale at a fixed price of $0.50, continuing the project's structured distribution ahead of its January 2026 SPL debut. HELSINKI, Dec. 08, 2025 (GLOBE NEWSWIRE) —

KLAR INVESTOR ALERT: Hagens Berman Scrutinizing Klarna (KLAR) Amid 102% Spike in Credit Loss Provision Risk Tied to Fair Financing Growth

KLAR INVESTOR ALERT: Hagens Berman Scrutinizing Klarna (KLAR) Amid 102% Spike in Credit Loss Provision Risk Tied to Fair Financing Growth Partner Reed Kathrein Investigating Whether Management Misrepresented Provision Trends and Lending Risk GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman has launched an

CEO.CA's Inside the Boardroom: Lahontan Gold CEO – New Permit Unlocks 50% of Land Package, Multiple Catalysts Ahead in 2026

Toronto, Ontario–(Newsfile Corp. – December 8, 2025) – CEO.CA (“CEO.CA”), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers. Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and

AVTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered in Avantor to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson

MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman

(NASDAQ:MLTX), SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025. “In specialized biotech cases, the core legal question is

MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman

MLTX 1-WEEK DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies? GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08,

Scroll to Top